Scandinavian Real Heart AB (Publ)
Scandinavian Real Heart AB (Publ) engages in the design and development of an artificial heart. The company develops Realheart TAH to treat advanced stage heart failure. It also develops RealVAD for pulsating left ventricle assist; PulsePump, a pulsating flow for heart and lung machines; and Sternal Prosthesis to fix the sternum after open-chest surgery. The company was founded in 1999 and is bas… Read more
Scandinavian Real Heart AB (Publ) (7820) - Net Assets
Latest net assets as of June 2025: €74.35 Million EUR
Based on the latest financial reports, Scandinavian Real Heart AB (Publ) (7820) has net assets worth €74.35 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€87.94 Million) and total liabilities (€13.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €74.35 Million |
| % of Total Assets | 84.54% |
| Annual Growth Rate | -15.42% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2.35 |
Scandinavian Real Heart AB (Publ) - Net Assets Trend (2021–2024)
This chart illustrates how Scandinavian Real Heart AB (Publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scandinavian Real Heart AB (Publ) (2021–2024)
The table below shows the annual net assets of Scandinavian Real Heart AB (Publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €67.34 Million | -17.92% |
| 2023-12-31 | €82.04 Million | -15.98% |
| 2022-12-31 | €97.65 Million | -12.26% |
| 2021-12-31 | €111.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scandinavian Real Heart AB (Publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 12515032900.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €67.34 Million | 100.00% |
| Total Equity | €67.34 Million | 100.00% |
Scandinavian Real Heart AB (Publ) Competitors by Market Cap
The table below lists competitors of Scandinavian Real Heart AB (Publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TVA Group Inc
PINK:TVAGF
|
$4.77 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
$4.78 Million |
|
Plaza Centers NV
WAR:PLZ
|
$4.78 Million |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
$4.78 Million |
|
Salarius Pharmaceuticals Inc
NASDAQ:SLRX
|
$4.77 Million |
|
Genesis Fertility Center Public Company Limited
BK:GFC
|
$4.77 Million |
|
Nam Song Hau Trading Investing Petroleum JSC
VN:PSH
|
$4.77 Million |
|
Interra Copper Corp
OTCQB:IMIMF
|
$4.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandinavian Real Heart AB (Publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 82,037,974 to 67,340,121, a change of -14,697,853 (-17.9%).
- Net loss of 34,350,238 reduced equity.
- New share issuances of 19,585,388 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-34.35 Million | -51.01% |
| Share Issuances | €19.59 Million | +29.08% |
| Other Changes | €67.00K | +0.1% |
| Total Change | €- | -17.92% |
Book Value vs Market Value Analysis
This analysis compares Scandinavian Real Heart AB (Publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €148.73 | €1.14 | x |
| 2022-12-31 | €130.49 | €1.14 | x |
| 2023-12-31 | €56.17 | €1.14 | x |
| 2024-12-31 | €32.27 | €1.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandinavian Real Heart AB (Publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-51.01%) is below the historical average (-39.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -9.42% | 0.00% | 0.00x | 1.06x | €-21.61 Million |
| 2022 | -14.33% | -139879.11% | 0.00x | 1.23x | €-23.75 Million |
| 2023 | -82.86% | 0.00% | 0.00x | 1.25x | €-76.18 Million |
| 2024 | -51.01% | 0.00% | 0.00x | 1.24x | €-41.08 Million |
Industry Comparison
This section compares Scandinavian Real Heart AB (Publ)'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $268,774,858
- Average return on equity (ROE) among peers: -81.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandinavian Real Heart AB (Publ) (7820) | €74.35 Million | -9.42% | 0.18x | $4.77 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $17.10 Million |
| Q-linea AB (publ) (3F80) | $163.19 Million | -164.65% | 0.41x | $9.23 Million |
| Guerbet SA (4G8) | $342.14 Million | 13.51% | 1.79x | $44.77 Million |
| aap Implantate AG (AAQ1) | $54.78 Million | 26.71% | 0.17x | $9.65 Million |
| Carmat SA (CXT) | $7.48 Million | -557.76% | 3.92x | $1.62 Million |
| elexxion AG (E8X) | $-0.01 | 0.00% | 0.00x | $199.10K |
| AETHLON MEDIC.NEW DL-001 (EJU) | $15.06 Million | -79.86% | 0.16x | $446.12K |
| Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) | $139.44 Million | 15.79% | 0.97x | $610.05 Million |
| Gaush Meditech Ltd (F7Y) | $1.70 Billion | 10.23% | 0.68x | $29.55 Million |